Rosiglitazone decreases 11β‐hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue
- 20 July 2007
- journal article
- clinical trial
- Published by Wiley in Clinical Endocrinology
- Vol. 67 (3) , 419-425
Abstract
Summary: Objective The peroxisome proliferator‐activated receptor‐γ (PPARγ) agonist rosiglitazone increases insulin sensitivity, which, in animal models, is comparable to the effect of a reduction in 11β‐hydroxysteroid dehydrogenase type 1 (11β‐HSD1) activity. We therefore investigated whether rosiglitazone‐induced insulin sensitivity is associated with changes in 11β‐HSD1 activity in different tissues.Methods An oral glucose tolerance test (OGTT) and a euglycaemic hyperinsulinaemic clamp were performed in seven male volunteers [age 59·3 ± 3·0 years, body mass index (BMI) 29·3 ± 4·1 kg/m2] with impaired glucose tolerance before and after 8 weeks of rosiglitazone treatment. To assess hepatic 11β‐HSD1 activity, serum cortisol levels were measured after oral administration of cortisone acetate. 11β‐HSD1 activity and mRNA expression were assessed in abdominal subcutaneous fat biopsies. Total‐body 11β‐HSD activities were estimated by calculating the urinary ratios of glucocorticoid metabolites.Results As expected, rosiglitazone improved insulin resistance and postprandial hyperglycaemia. In parallel, 11β‐HSD1 mRNA expression [100 ± 0% (reference) vs. 68·5 ± 9·3%, P < 0·01] and activity [0·18 ± 0·02 vs. 0·13 ± 0·02 pmol/min/mg, P < 0·05] decreased in abdominal subcutaneous fat, while an increase in hepatic 11β‐HSD1 activity was detected [the area under the curve (AUC) for the cortisol/cortisone ratio was 1319 ± 76 vs. 955 ± 59; P < 0·05]. No changes in BMI, waist‐to‐hip ratio (WHR) and whole‐body 11β‐HSD1 activity were found.Conclusions Part of the beneficial effects of rosiglitazone may be mediated by a reduction in the 11β‐HSD1 mRNA expression and activity in subcutaneous abdominal fat.Keywords
This publication has 41 references indexed in Scilit:
- Adipose Tissue Metabolism and CD11b Expression on Monocytes in Obese HypertensivesHypertension, 2005
- Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissueAmerican Journal of Physiology-Endocrinology and Metabolism, 2005
- The Metabolic Syndrome X And Peripheral Cortisol SynthesisExperimental and Clinical Endocrinology & Diabetes, 2002
- Expression of the mRNA Coding for 11 -Hydroxysteroid Dehydrogenase Type 1 in Adipose Tissue from Obese Patients: An in Situ Hybridization StudyThe Journal of Clinical Endocrinology & Metabolism, 2002
- A Transgenic Model of Visceral Obesity and the Metabolic SyndromeScience, 2001
- Minireview: 11 -Hydroxysteroid Dehydrogenase Type 1-- A Tissue-Specific Amplifier of Glucocorticoid ActionEndocrinology, 2001
- Tissue-Specific Dysregulation of Cortisol Metabolism in Human ObesityThe Journal of Clinical Endocrinology & Metabolism, 2001
- Mechanisms of dysregulation of 11 beta-hydroxysteroid dehydrogenase type 1 in obese Zucker ratsJournal of Endocrinology, 2000
- Troglitazone prevents and reverses dexamethasone induced insulin resistance on glycogen synthesis in 3T3 adipocytesBritish Journal of Pharmacology, 2000
- Understanding the Role of Glucocorticoids in Obesity: Tissue-Specific Alterations of Corticosterone Metabolism in Obese Zucker RatsEndocrinology, 2000